Talis Biomedical Corporation (TLIS)
USD 1.6
(6.67%)
USD 1.6
(6.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -66.04 Million USD | 47.28% |
| 2022 | -106.3 Million USD | 39.97% |
| 2021 | -191.81 Million USD | -112.14% |
| 2020 | -90.42 Million USD | -248.13% |
| 2019 | -25.97 Million USD | -24.97% |
| 2018 | -20.78 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -8.88 Million USD | 3.04% |
| 2024 Q2 | -8.49 Million USD | 31.48% |
| 2023 Q4 | -13.88 Million USD | 17.12% |
| 2023 FY | - USD | 47.28% |
| 2023 Q1 | -18.82 Million USD | 33.04% |
| 2023 Q2 | -16.22 Million USD | 13.81% |
| 2023 Q3 | -16.75 Million USD | -3.27% |
| 2022 Q2 | -26.29 Million USD | 19.36% |
| 2022 FY | - USD | 39.97% |
| 2022 Q4 | -28.11 Million USD | -22.97% |
| 2022 Q3 | -22.86 Million USD | 13.05% |
| 2022 Q1 | -32.6 Million USD | -14.32% |
| 2021 Q4 | -28.52 Million USD | 25.31% |
| 2021 Q1 | -60.52 Million USD | -37.6% |
| 2021 FY | - USD | -112.14% |
| 2021 Q2 | -64.16 Million USD | -6.03% |
| 2021 Q3 | -38.18 Million USD | 40.49% |
| 2020 Q3 | -29.39 Million USD | -199.02% |
| 2020 FY | - USD | -248.13% |
| 2020 Q4 | -43.98 Million USD | -49.62% |
| 2020 Q2 | -9.83 Million USD | -36.35% |
| 2020 Q1 | -7.21 Million USD | -8.0% |
| 2019 FY | - USD | -24.97% |
| 2019 Q4 | -6.67 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acutus Medical, Inc. | -13.48 Million USD | -389.694% |
| Biotricity, Inc. | -8.82 Million USD | -648.108% |
| Cell MedX Corp. | - USD | Infinity% |
| Dynatronics Corporation | -976 Thousand USD | -6666.85% |
| Nemaura Medical Inc. | -7.28 Million USD | -806.333% |
| PetVivo Holdings, Inc. | -10.49 Million USD | -529.33% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -3064.668% |
| Sonendo, Inc. | -54.76 Million USD | -20.59% |
| Telesis Bio, Inc. | -40.49 Million USD | -63.102% |
| Viveve Medical, Inc. | -20.61 Million USD | -220.342% |